Andrea Chicca

Company: Synendos Therapeutics Inc.

Job title: Co-Founder & Chief Executive Officer

Seminars:

Selective Endocannabinoid Re-uptake Inhibitors (SERIs): A New Class of ECS Modulators for Safe & Effective Treatment of Neuropsychiatric Disorders 3:15 pm

Presenting the mode of action of SERIs to inhibit eCB re-uptake across plasma membranes by targeting a newly identified protein in the ECS SERIs represent a new class of ECS modulators characterized by a distinctive pharmacology profile within the ECS Showcasing SYT-510, a clinical candidate of the SERI class.Read more

day: Conference Day 1

Selective Endocannabinoid Re-uptake Inhibitors (SERIs): A New Class of ECS Modulators for Safe & Effective Treatment of Neuropsychiatric Disorders 4:15 pm

Presenting the mode of action of SERIs to inhibit eCB re-uptake across plasma membranes by targeting a newly identified protein in the ECS SERIs represent a new class of ECS modulators characterized by a distinctive pharmacology profile within the ECS Showcasing SYT-510, a clinical candidate of the SERI classRead more

day: Day One PM